X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (887) 887
Publication (88) 88
Book Chapter (5) 5
Book Review (5) 5
Conference Proceeding (3) 3
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (431) 431
index medicus (429) 429
humans (424) 424
male (292) 292
female (201) 201
rats (193) 193
pharmacology & pharmacy (158) 158
malate dehydrogenase - metabolism (150) 150
oncology (128) 128
mice (125) 125
cancer (120) 120
sunitinib malate (118) 118
metabolism (111) 111
malate (109) 109
analysis (91) 91
malates - therapeutic use (89) 89
biochemistry & molecular biology (88) 88
malates - metabolism (88) 88
enzymes (87) 87
middle aged (85) 85
malate dehydrogenase (84) 84
mitochondria (84) 84
adult (79) 79
physiological aspects (77) 77
proteins (73) 73
tyrosine kinase inhibitor (69) 69
research (68) 68
aged (66) 66
care and treatment (60) 60
antineoplastic agents - therapeutic use (59) 59
article (59) 59
cell biology (57) 57
cell line, tumor (57) 57
indoles - therapeutic use (56) 56
medicine (55) 55
pyrroles - therapeutic use (54) 54
research article (54) 54
oxidative stress (53) 53
rats, wistar (51) 51
sunitinib (50) 50
malates - chemistry (49) 49
multidisciplinary sciences (49) 49
expression (48) 48
health aspects (48) 48
liver - enzymology (48) 48
glucose (45) 45
l-lactate dehydrogenase - metabolism (45) 45
liver - metabolism (45) 45
tumors (45) 45
endothelial growth-factor (43) 43
inhibition (43) 43
malate dehydrogenase - genetics (43) 43
carcinoma, renal cell - drug therapy (42) 42
kidney neoplasms - drug therapy (42) 42
malates - pharmacology (42) 42
chemotherapy (41) 41
gene expression (41) 41
liver (41) 41
science (41) 41
liver - drug effects (40) 40
medicine & public health (40) 40
mitochondria - metabolism (40) 40
toxicology (40) 40
time factors (39) 39
biochemistry (38) 38
metastasis (38) 38
apoptosis (37) 37
indoles - administration & dosage (37) 37
physiology (36) 36
pyrroles - administration & dosage (36) 36
metabolites (35) 35
neurosciences (35) 35
rodents (35) 35
dehydrogenases (34) 34
treatment outcome (34) 34
antineoplastic agents (33) 33
endocrinology & metabolism (33) 33
glycolysis (33) 33
indoles - adverse effects (33) 33
pyrroles - adverse effects (33) 33
angiogenesis (32) 32
antitumor-activity (32) 32
cells (32) 32
toxicity (32) 32
antimitotic agents (31) 31
antineoplastic agents - administration & dosage (31) 31
biology (31) 31
dehydrogenase (31) 31
disease models, animal (31) 31
drug delivery systems (31) 31
energy metabolism (31) 31
hydrogen-ion concentration (31) 31
neoplasms - drug therapy (31) 31
therapy (31) 31
dose-response relationship, drug (30) 30
in-vivo (30) 30
malic acid (30) 30
medicine, research & experimental (30) 30
proteomics (30) 30
antineoplastic agents - adverse effects (29) 29
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (810) 810
German (29) 29
Russian (27) 27
French (11) 11
Italian (7) 7
Japanese (7) 7
Spanish (2) 2
Chinese (1) 1
Czech (1) 1
Hungarian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2006, Volume 24, Issue 35, pp. 5601 - 5608
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 68, Issue 3, pp. 516 - 522
Abstract Background Limited data exist on the economic consequences of implementing targeted therapy (TT) for metastatic renal cell carcinoma (RCC) in a... 
Urology | Metastatic renal cell carcinoma | Economic analysis | Population-based | Observational | National | Targeted therapy | Cost analysis | Implementation | 1ST-LINE TREATMENT | COST-EFFECTIVENESS | FINLAND | EVEROLIMUS | SUNITINIB MALATE | CANCER | INTERFERON-ALPHA | IMMUNOTHERAPY | 2ND-LINE TREATMENT | UROLOGY & NEPHROLOGY | Bevacizumab - therapeutic use | Everolimus - economics | Radiotherapy - economics | Humans | Middle Aged | Niacinamide - economics | Male | Antineoplastic Agents - therapeutic use | Efficiency | Employment - economics | Aged, 80 and over | Sirolimus - economics | Indoles - economics | Bevacizumab - economics | Costs and Cost Analysis | Protein Kinase Inhibitors - economics | Niacinamide - therapeutic use | Antineoplastic Agents - economics | Carcinoma, Renal Cell - economics | Indoles - therapeutic use | Ambulatory Care - economics | Phenylurea Compounds - economics | Drug Costs | Niacinamide - analogs & derivatives | Fluorouracil - economics | Interleukin-2 - economics | Interleukin-2 - therapeutic use | Immunologic Factors - economics | Fluorouracil - therapeutic use | Neoplasm Metastasis - drug therapy | Angiogenesis Inhibitors - therapeutic use | Adult | Angiogenesis Inhibitors - economics | Everolimus - therapeutic use | Female | Registries | Pyrroles - economics | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Radiography - economics | Interferon-alpha - therapeutic use | Interferon-alpha - economics | Phenylurea Compounds - therapeutic use | Kidney Neoplasms - economics | Health Care Costs | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Denmark | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Hospitalization - economics | Immunologic Factors - therapeutic use | Economic aspects | Metastasis | Carcinoma, Renal cell
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2012, Volume 109, Issue 8, pp. 2784 - 2789
Journal Article
Breast, The, ISSN 0960-9776, 2013, Volume 22, Issue 5, pp. 650 - 656
Abstract Purpose This randomized, open-label phase II study compared the efficacy of sunitinib monotherapy with that of single-agent standard-of-care (SOC)... 
Hematology, Oncology and Palliative Medicine | Sunitinib | Phase II | Standard-of-care chemotherapy | Receptor tyrosine kinases | Triple-negative breast cancer | 1ST-LINE TREATMENT | METASTASIS | MALATE | SU11248 | OBSTETRICS & GYNECOLOGY | INVASION | ONCOLOGY | KIT | CARCINOMAS | TYROSINE KINASE INHIBITOR | GROWTH-FACTOR | EXPRESSION | Pyrroles - pharmacokinetics | Capecitabine | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Hand-Foot Syndrome - etiology | Triple Negative Breast Neoplasms - drug therapy | Fluorouracil - therapeutic use | Taxoids - therapeutic use | Deoxycytidine - therapeutic use | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Triple Negative Breast Neoplasms - pathology | Aged, 80 and over | Pyrroles - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Chemotherapy, Adjuvant | Neutropenia - chemically induced | Pyrroles - therapeutic use | Fluorouracil - analogs & derivatives | Survival Rate | Thrombocytopenia - chemically induced | Paclitaxel - therapeutic use | Disease-Free Survival | Indoles - adverse effects | Indoles - pharmacokinetics | Indoles - therapeutic use | Aged | Anthracyclines - therapeutic use | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical research | Care and treatment | Chemotherapy | Clinical trials | Medicine, Experimental | Breast cancer | Antineoplastic agents | Patients | Standards | Cancer
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 11/2013, Volume 171, Issue 3, pp. 322 - 329
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 07/2010, Volume 66, Issue 2, pp. 357 - 371
Journal Article